Beneficial effect of polaprezinc on cardiac function post-myocardial infarction: A prospective and randomized clinical trial.

Abstract

BACKGROUND:

Polaprezinc is clinically used for the treatment of gastric ulcers. It induces the mobilization of mesenchymal stem cells and the mRNA expression of insulin-like growth factor-1 in vascular endothelial cells in order to protect injured gastric tissue or skin.

METHODS:

The current study population included 50 patients with primary acute myocardial infarction (AMI). After percutaneous coronary intervention, the subjects were randomly divided into 2 groups, namely, the nonpolaprezinc and polaprezinc groups. Peripheral blood and urinary samples were collected in a specific time to analyze zinc concentration, cardiac enzymes, and the levels of the inflammation marker interleukin-6. To evaluate the cardiac function, echocardiography was performed upon admission to the hospital and at 9 months post-AMI.

RESULTS:

The urine and blood zinc levels of the polaprezinc group were higher compared with those of the non-polaprezinc group at 8 days after percutaneous coronary intervention. The mean interleukin-6/maximal creatine phosphokinase level was significantly reduced in the polaprezinc group (0.024 [0.003-0.066] vs. 0.076 [0.015-0.212], respectively; P = .045). In addition, echocardiography revealed that the ejection fraction of the nonpolaprezinc group was not significantly increased between day 3 and 9 months post-AMI (53 [49-60.8] vs. 59.5 [52-69.3], respectively; P = .015). However, a significant increase was detected in the ejection fraction of the polaprezinc group at the 2 time points (54 [51-57] vs. 62 [55-71], respectively; P < .01).

CONCLUSIONS:

The results of the present study suggest that polaprezinc has an anti-inflammatory effect and improves cardiac function after AMI.

• Authors: Fumitsugu Yoshikawa, Tetsu Nakajima, Masaharu Hanada, Kazuo Hirata, Tohru Masuyama, Ryuichi Aikawa
• Journal: Medicine (Medicine (Baltimore)) Vol. 98 Issue 10 Pg. e14637 (Mar 2019) ISSN: 1536-5964 [Electronic] United States
• PMID: 30855449 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Inflammatory Agents
• Biomarkers
• Cardiovascular Agents
• Organometallic Compounds
• Zinc Compounds
• polaprezinc
• Carnosine
• Zinc

Topics

• Aged
• Anti-Inflammatory Agents (therapeutic use)
• Biomarkers (blood, urine)
• Cardiovascular Agents (therapeutic use)
• Carnosine (analogs & derivatives, therapeutic use)
• Electrocardiography
• Female
• Humans
• Male
• Middle Aged
• Myocardial Infarction (diagnostic imaging, metabolism, therapy)
• Organometallic Compounds (therapeutic use)
• Percutaneous Coronary Intervention
• Treatment Outcome
• Zinc (blood, urine)
• Zinc Compounds (therapeutic use)